cefditoren pivoxil profile

ID Source	ID
PubMed CID	6437877
CHEMBL ID	454446
CHEBI ID	560555
SCHEMBL ID	182876
MeSH ID	M0161357

Synonym
AB01274730-01
me-1207
spectracef
meiact
D01628
cdtr-pi
meiact (tn)
spectracef (tn)
cefditoren pivoxil (jp17/usan)
7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-(2-(4-methylthiazol-5-yl)ethenyl)cephem-4-carboxylic acid pivaloyloxymethyl ester
cefditoren pivaloyloxymethyl ester
cefditoren (pivoxil)
me 1207
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-((1z)-2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-,2,2-dimethyl-1-oxopropoxy)methyl ester, (6r,7r)-
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r-(3(z),6alpha,7beta(z)))-
cefditorin
ccris 7768
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r-(3(z),6-alpha,7-beta-(z)))-
cefditoren pi voxil
cefditoren pivoxil [jan]
CHEBI:560555 ,
[(2,2-dimethylpropanoyl)oxy]methyl 7beta-(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido-3-[(z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-3,4-didehydrocepham-4-carboxylic acid
pivaloyloxymethyl (+)-(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
[(2,2-dimethylpropanoyl)oxy]methyl (6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
2,2-dimethylpropanoyloxymethyl (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
cas-117467-28-4
tox21_113197
dtxcid5028669
dtxsid2048743 ,
nsc-759098
unii-78tha212dh
me1207
78tha212dh ,
cefditoren pivoxil [usan:jan]
nsc 759098
CHEMBL454446
cefditoren pivoxil [vandf]
(+)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-((z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate pivaloyloxy methyl ester, 7(sup 2)-(z)-(o-methyloxime)
cefditoren pivaloyloxymethyl ester [mi]
cefditoren pivoxil [mart.]
cefditoren pivoxil [usan]
cefditoren pivoxil [orange book]
cefditoren pivoxil [who-dd]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(((2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-((1z)-2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r,7r)-
S1768
AKOS025311444
CS-1949
HY-17452A
SCHEMBL182876
(pivaloyloxy)methyl (6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((z)-2-(4-methylthiazol-5-yl)vinyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
C2856
AB01274730_02
cefditoren-pivoxil
(6r,7r)-(pivaloyloxy)methyl 7-((z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((z)-2-(4-methylthiazol-5-yl)vinyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
mfcd00933166
AS-12951
BRD-K72167406-001-03-9
CCG-270254
NCGC00095175-08
1448435-17-3
cefditoren pivoxil hcl
pivaloyloxymethyl (+)-(6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl)amino)-3-((z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-((1z)-2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-,(2,2-dimethyl-1-oxopropoxy)methyl ester,(6r,7r)-
((2,2-dimethylpropanoyl)oxy)methyl (6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl)amino)-3-((z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
((2,2-dimethylpropanoyl)oxy)methyl 7beta-(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido-3-((z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl)-3,4-didehydrocepham-4-carboxylic acid
2,2-dimethylpropanoyloxymethyl (6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetylamino)-3-((1z)-2-(4-methylthiazol-5-yl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
cefditoren pivoxil (mart.)

Excerpt	Reference	Relevance
" This study described its pharmacodynamic profile in plasma and epithelial lining fluid (ELF)."	( Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Bulitta, J; Drusano, GL; Hinder, M; Kinzig-Schippers, M; Lodise, TP; Loos, U; Sörgel, F; Vogel, F, 2008)	0.35

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The experimental bactericidal activity of cefditoren is maintained over the dosing interval regardless of the presence of a mutation in the ftsI gene or beta-lactamase production."	( influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi Aguilar, L; Alou, L; Cafini, F; Coronel, P; Echeverría, O; Giménez, MJ; González, N; Prieto, J; Sevillano, D; Torrico, M, 2007)	0.34
" Design and synthesis, in vitro and in vivo evaluation of diversified prodrugs of ertapenem, one of the only once daily dosed carbapenems is described."	( Design, synthesis, and evaluation of prodrugs of ertapenem. Bradley, P; Cama, L; Hafey, MJ; Ji, C; Meinke, PT; Nicoll-Griffith, DA; Olsen, DB; Rindgen, D; Singh, SB; Soll, R; Sun, W; Suzuki, T; Wang, L; Wang, N; Wu, H; Yu, H; Zhang, B, 2013)	0.39

Role	Description
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
antibacterial drug	A drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pivaloyloxymethyl ester	A acetal obtained from a carboxylic acid by replacement of the hydrogen attached to the carboxy group by a pivaloyloxymethyl group.
1,3-thiazoles
oxime O-ether	O-organyl oximes R2C=NOR' (R' =/= H).
cephams	Natural and synthetic antibiotics containing the 5-thia-1-azabicyclo[4.2.0]octan-8-one nucleus; generally assumed to have the 6R configuration, unless otherwise specified.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (224)

Assay ID	Title	Year	Journal	Article
AID521228	Ratio of drug level in epithelial lining fluid to plasma of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 3 to 4 hrs prior to bronchoscopy by LC-MS analysis relative to control	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID351218	Half life of free unbound fraction in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535645	Antimicrobial activity against Group B Streptococcus serotype Ia N1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID351412	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 30 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521656	Antimicrobial activity against Escherichia coli S6 expressing extended-spectrum beta-lactamase TEM-116 and SHV-12 after 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351431	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 36 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535636	Antimicrobial activity against Group B streptococcus serotype VI R4 harboring Q557E mutation in PBP 2X and T567I, Y262N mutations in PBP 2B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID567472	Antimicrobial activity against gBLNAR Haemophilus influenzae by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID535634	Antimicrobial activity against Group B streptococcus serotype VI R6 harboring F395L, V405A, R433H, H438Y, A374V and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID521654	Antimicrobial activity against Escherichia coli S4 expressing inhibitor-resistant TEM-34 after 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521323	Antimicrobial activity against rifampin-resistant Haemophilus influenzae Rd clone by broth dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID351426	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 28 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535340	Antimicrobial activity against Streptococcus pneumoniae clinical isolates by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID535360	Antimicrobial activity against Haemophilus influenzae clinical isolates by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID521653	Antimicrobial activity against Escherichia coli S3 overexpressing penicillinase TEM-1after 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351403	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID567471	Antimicrobial activity against gLow-BLNAR Haemophilus influenzae by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID521365	AUC (0 to infinity) in epithelial lining fluid of patient scheduled to undergo bronchoscopy at 400 mg/kg, po administered during fasting condition by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID521482	Antimicrobial activity against Escherichia coli S3 overexpressing penicillinase TEM-1 after 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521676	Antimicrobial activity against Escherichia coli S1 expressing penicillinase TEM-1 assessed as log reduction in bacterial count upto 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521230	Drug level in epithelial lining fluid of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 3 to hrs prior to bronchoscopy by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID535673	Antimicrobial activity against beta-lactamase negative, ampicillin-resistant Haemophilus influenzae expressing fst1 mutant gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID521363	Apparent volume of distribution with respect to bioavailability in in epithelial lining fluid of patient scheduled to undergo bronchoscopy at 400 mg/kg, po administered during fasting condition by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID535669	Antimicrobial activity against beta-lactamase positive, ampicillin-clavulanic acid resistant Haemophilus influenzae expressing fst1 mutant gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID521372	fT>MIC in Streptococcus pneumoniae-infected patient scheduled to undergo fiber-optic bronchoscopy at => 3 mg/L	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID351223	fCmax in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351424	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 24 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521663	Antimicrobial activity against Escherichia coli S6 expressing extended-spectrum beta-lactamase TEM-116 and SHV-12 after 24 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID567470	Antimicrobial activity against gBLNAS Haemophilus influenzae by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521364	Apparent oral clearance in patients scheduled to undergo optic-fiber bronchoscopy at 400 mg/kg, po administered during fasting condition by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID521368	Absorption constant, Ka in patient scheduled to undergo bronchoscopy at 400 mg/kg, po administered during fasting condition by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID521467	Drug level in human urine at 400 mg/kg, po after 8 to 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521373	T>MIC in Streptococcus pneumoniae-infected patient scheduled to undergo fiber-optic bronchoscopy at =< 3 mg/L	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID351213	AUC (0 to 24 hrs) in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351417	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535346	Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as susceptible isolates by PK/PD technique	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID351415	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 36 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID351414	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 36 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351228	T>MIC in beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected kinetic model at simulated total serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351408	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 24 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521675	Antimicrobial activity against Escherichia coli S2 expressing penicillinase TEM-1 assessed as log reduction in bacterial count upto 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351233	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521655	Antimicrobial activity against Escherichia coli S5 expressing extended-spectrum beta-lactamase TEM-116 after 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521668	Antimicrobial activity against Escherichia coli S4 expressing inhibitor-resistant TEM-34 assessed as log reduction in bacterial count after 4 to 24 hrs in presence of magnesium ions	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521366	AUC (0 to infinity) in plasma of patient scheduled to undergo bronchoscopy at 400 mg/kg, po administered during fasting condition by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID521375	T>MIC in Streptococcus pneumoniae-infected patient scheduled to undergo fiber-optic bronchoscopy at 0.03 mg/L	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID351395	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 28 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351427	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 28 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535681	Antimicrobial activity against beta-lactamase negative Haemophilus influenzae expressing fst1 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID438297	Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID521686	Antimicrobial activity against Escherichia coli S5 expressing extended-spectrum beta-lactamase TEM-116 assessed as log reduction in bacterial count upto 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID535647	Antimicrobial activity against Group B Streptococcus serotype V 2603 V/R harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID372547	Antibacterial activity against genetically beta-lactamase-negative ampicillin-susceptible Haemophilus influenzae type b without amino acid substitutions in ftsI gene and bla gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID351227	T>MIC in beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected kinetic model at simulated free serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521674	Antimicrobial activity against Escherichia coli S4 expressing inhibitor-resistant TEM-34assessed as log reduction in bacterial count after 4 to 24 hrs in presence of calcium ions	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521664	Antimicrobial activity against Escherichia coli S7 expressing extended-spectrum beta-lactamase SHV-12 and penicillinase TEM-1 after 24 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521650	Antimicrobial activity against Escherichia coli S7 expressing extended-spectrum beta-lactamase SHV-12 and penicillinase TEM-1 after 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351655	Protein binding in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID533205	Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as susceptible isolates by PK/PD technique	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID521371	fT>MIC in Streptococcus pneumoniae-infected patient scheduled to undergo fiber-optic bronchoscopy at 0.03 mg/L	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID535643	Antimicrobial activity against Group B streptococcus serotype III N3 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID372549	Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in highly mutated locus Ser-385 of ftsI gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID351205	Cmax in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID559859	Antimicrobial activity against Streptococcus agalactiae clinical isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.
AID351420	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535644	Antimicrobial activity against Group B streptococcus serotype Ib N2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID521470	Antimicrobial activity against Escherichia coli S2 expressing penicillinase TEM-1	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID535642	Antimicrobial activity against Group B streptococcus serotype VI N4 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID521483	Antimicrobial activity against Escherichia coli S4 expressing inhibitor-resistant TEM-34 after 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521677	Antimicrobial activity against Escherichia coli S5 expressing extended-spectrum beta-lactamase TEM-116 assessed as log reduction in bacterial count from 3 to 24 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID521474	Antimicrobial activity against Escherichia coli S6 expressing extended-spectrum beta-lactamase TEM-116 and SHV-12	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521469	Antimicrobial activity against Escherichia coli S1 expressing penicillinase TEM-1	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351226	T>MIC in beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected kinetic model at simulated total serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351410	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 28 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID521687	Antimicrobial activity against Escherichia coli S6 expressing extended-spectrum beta-lactamase TEM-116 and SHV-12assessed as log reduction in bacterial count upto 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521464	AUC in human serum at 400 mg/kg, po	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521651	Antimicrobial activity against Escherichia coli S1 expressing penicillinase TEM-1 after 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521468	Antimicrobial activity against Escherichia coli	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351423	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521466	Drug level in human urine at 400 mg/kg, po after 2 to 4 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521673	Antimicrobial activity against Escherichia coli S3 overexpressing penicillinase TEM-1 assessed as log reduction in bacterial count after 4 to 24 hrs in presence of calcium ions	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521660	Antimicrobial activity against Escherichia coli S3 overexpressing penicillinase TEM-1 after 24 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID535356	Antimicrobial activity against Streptococcus pyogenes clinical isolates by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID521472	Antimicrobial activity against Escherichia coli S4 expressing inhibitor-resistant TEM-34	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351429	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 30 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID351217	fAUC (0 to 24 hrs) in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351206	Antibacterial activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae by microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521227	Apparent volume of distribution with respect to bioavailability in patient scheduled to undergo bronchoscopy at 400 mg/kg, po administered during fasting condition by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID351432	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351407	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521671	Antimicrobial activity against Escherichia coli S1 expressing penicillinase TEM-1 assessed as log reduction in bacterial count after 4 to 24 hrs in presence of calcium ions	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351225	T>MIC in ampicillin-susceptible Haemophilus influenzae infected kinetic model at simulated free serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521477	Clearance in human at 400 mg/kg, po after 3 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351234	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID438298	Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID535677	Antimicrobial activity against beta-lactamase positive Haemophilus influenzae expressing fst1 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID521232	Drug level in plasma of epithelial lining fluid of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 1 to 2 hrs prior to bronchoscopy by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID351237	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 24 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521658	Antimicrobial activity against Escherichia coli S1 expressing penicillinase TEM-1 after 24 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID567475	Antimicrobial activity against gBLPACR-2 Haemophilus influenzae by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID351236	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 24 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351428	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 30 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351231	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521661	Antimicrobial activity against Escherichia coli S4 expressing inhibitor-resistant TEM-34 after 24 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351413	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 30 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351402	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351238	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 28 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521672	Antimicrobial activity against Escherichia coli S2 expressing penicillinase TEM-1 assessed as log reduction in bacterial count after 4 to 24 hrs in presence of calcium ions	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521374	T>MIC in Streptococcus pneumoniae-infected patient scheduled to undergo fiber-optic bronchoscopy at 0.06 mg/L	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID351399	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 36 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535638	Antimicrobial activity against Group B streptococcus serotype VI R2 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID351210	Tmax in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID567474	Antimicrobial activity against gBLPACR-1 Haemophilus influenzae by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID351229	T>MIC in beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected kinetic model at simulated free serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351425	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 24 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351406	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535633	Antimicrobial activity against Group B streptococcus serotype Ia R7 harboring T77I, F395V and S353F in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and Y470F in PBP 1A by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID772151	Oral bioavailability in human	2013	ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8	Design, synthesis, and evaluation of prodrugs of ertapenem.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID521665	Antimicrobial activity against Escherichia coli S1 expressing penicillinase TEM-1 assessed as log reduction in bacterial count after 4 to 24 hrs in presence of magnesium ions	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID535635	Antimicrobial activity against Group B streptococcus serotype VI R5 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID521369	fT>MIC in Streptococcus pneumoniae-infected patient scheduled to undergo fiber-optic bronchoscopy at =< 3 mg/L	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID535639	Antimicrobial activity against Group B streptococcus serotype VI R1 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID351396	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 30 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351419	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521324	Antimicrobial activity against beta lactamase-nonproducing ampicillin-resistant Haemophilus influenzae MSC06647 isolate harboring Asn526Lys mutation in penicillin-binding protein 3 by broth dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID351401	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID351405	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351208	Antibacterial activity against ampicillin-susceptible Haemophilus influenzae by microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351409	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 24 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID372548	Antibacterial activity against genetically beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b with an amino acid substitution in variable mutated locus Asn-526 or Arg-517 of ftsI gene by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
AID521678	Cmax in human serum at 400 mg/kg, po	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID535632	Antimicrobial activity against Group B streptococcus R8 harboring T77I, S353F and A514V in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and G527V in PBP 1A by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID521231	Drug level in epithelial lining fluid of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 2 to 3 hrs prior to bronchoscopy by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID351230	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521478	Clearance in human at 400 mg/kg, po after 3 hrs to 5 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521670	Antimicrobial activity against Escherichia coli S3 overexpressing penicillinase TEM-1 assessed as log reduction in bacterial count upto 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521475	Antimicrobial activity against Escherichia coli S7 expressing extended-spectrum beta-lactamase SHV-12 and penicillinase TEM-1	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521657	Antimicrobial activity against Escherichia coli S7 expressing extended-spectrum beta-lactamase SHV-12 and penicillinase TEM-1 after 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351235	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521659	Antimicrobial activity against Escherichia coli S2 expressing penicillinase TEM-1after 24 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351398	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 36 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521481	Antimicrobial activity against Escherichia coli S2 expressing penicillinase TEM-1 after 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID535637	Antimicrobial activity against Group B streptococcus serotype Ib R3 harboring Q557E, A400V mutations in PBP 2X and T567I, G539E mutations in PBP 2B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID351430	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 36 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521667	Antimicrobial activity against Escherichia coli S3 overexpressing penicillinase TEM-1 assessed as log reduction in bacterial count after 4 to 24 hrs in presence of magnesium ions	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521480	Antimicrobial activity against Escherichia coli S1 expressing penicillinase TEM-1 after 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521360	Drug level in plasma of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 3 to hrs prior to bronchoscopy by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID351397	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 30 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID351207	Antibacterial activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae by microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID521370	fT>MIC in Streptococcus pneumoniae-infected patient scheduled to undergo fiber-optic bronchoscopy at 0.06 mg/L	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID521471	Antimicrobial activity against Escherichia coli S3 overexpressing penicillinase TEM-1	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID351421	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID351232	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521648	Antimicrobial activity against Escherichia coli S5 expressing extended-spectrum beta-lactamase TEM-116 after 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID521226	Ratio of drug level in epithelial lining fluid to plasma of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 2 to 3 hrs prior to bronchoscopy by LC-MS analysis relative to control	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID521325	Antimicrobial activity against beta lactamase-nonproducing ampicillin-resistant Haemophilus influenzae MSC06663 isolate harboring Met377Ile, Ser385Thr and Asn526Lys mutations in penicillin-binding protein 3 by broth dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID521376	T>MIC in Streptococcus pneumoniae-infected patient scheduled to undergo fiber-optic bronchoscopy at 0.0125 mg/L	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID521476	Volume of distribution in human at 400 mg/kg, po	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351211	Half life in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351433	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 4 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521465	Half-life in human serum at 400 mg/kg, po	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID351416	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535640	Antimicrobial activity against Group B streptococcus serotype Ib C2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID351411	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated free serum concentration of 400 mg, po bid after 28 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351400	Bactericidal activity against ampicillin-susceptible Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID351212	fTmax in beta lactamase-negative Haemophilus influenzae pharmacokinetic simulation model at simulated human serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID535646	Antimicrobial activity against Group B Streptococcus serotype III NEM 316 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID351418	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 6 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521666	Antimicrobial activity against Escherichia coli S2 expressing penicillinase TEM-1 assessed as log reduction in bacterial count after 4 to 24 hrs in presence of magnesium ions	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521473	Antimicrobial activity against Escherichia coli S5 expressing extended-spectrum beta-lactamase TEM-116	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID521669	Antimicrobial activity against Escherichia coli S4 expressing inhibitor-resistant TEM-34 assessed as log reduction in bacterial count upto 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID521649	Antimicrobial activity against Escherichia coli S6 expressing extended-spectrum beta-lactamase TEM-116 and SHV-12 after 8 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521479	Clearance in human at 400 mg/kg, po after 5 hrs to 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID521662	Antimicrobial activity against Escherichia coli S5 expressing extended-spectrum beta-lactamase TEM-116 after 24 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521361	Drug level in plasma of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 2 to 3 hrs prior to bronchoscopy by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID521652	Antimicrobial activity against Escherichia coli S2 expressing penicillinase TEM-1after 12 hrs	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of ce
AID535641	Antimicrobial activity against Group B streptococcus serotype V C1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID521367	Ratio of AUC (0 to infinity) in epithelial lining fluid to AUC (0 to infinity) in plasma of patient scheduled to undergo bronchoscopy at 400 mg/kg, po administered during fasting condition by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID351404	Bactericidal activity against beta lactamase-negative ampicillin-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 8 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID351422	Bactericidal activity against beta lactamase-positive amoxicillin-clavulanic acid-resistant Haemophilus influenzae infected in kinetic model assessed as reduction in colony count at simulated total serum concentration of 400 mg, po bid after 12 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID567473	Antimicrobial activity against gBLPAR-TEM1 Haemophilus influenzae by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID351224	T>MIC in ampicillin-susceptible Haemophilus influenzae infected kinetic model at simulated total serum concentration of 400 mg, po bid after 48 hrs	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhi
AID521229	Ratio of drug level in epithelial lining fluid to plasma of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 1 to 2 hrs prior to bronchoscopy by LC-MS analysis relative to control	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID521362	Drug level in plasma of patient scheduled to undergo fiber-optic bronchoscopy at 400 mg/kg, po administered during fasting condition measured on 1 to 2 hrs prior to bronchoscopy by LC-MS analysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (50.00)	29.6817
2010's	7 (38.89)	24.3611
2020's	2 (11.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (5.26%)	5.53%
Reviews	1 (5.26%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (89.47%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
Multicentre, Prospective, Comparative, Randomized, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of Cefditoren Pivoxil vs. Ciprofloxacin in Uncomplicated Acute Cystitis [NCT00598403]	Phase 3	611 participants (Actual)	Interventional	2007-11-30	Completed
A Comparison of Cefditoren Pivoxil 10 mg/kg/Day and Cefditoren Pivoxil 20 mg/kg/Day in Treatment of Childhood With Acute Rhinosinusitis [NCT01553006]	Phase 4	120 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia [NCT04709172]	Phase 4	20 participants (Actual)	Interventional	2021-01-05	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Classes	Roles
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.45	2	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.05	1	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.96	4	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	2.05	1	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	3.55	8	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.74	3	cyclic ketone; erythromycin
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	2.05	1	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	3.55	8	penicillin allergen; penicillin	antibacterial drug
cefotiam Cefotiam: One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.. cefotiam : A cephalosporin with ({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl and (2-amino-1,3-thiazol-4-yl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. A third generation beta-lactam cephalosporin antibiotic, it is active against a broad spectrum of both Gram positive and Gram negative bacteria.	2.45	2	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.74	3	cephalosporin	antibacterial drug; drug allergen
cefprozil [no description available]	2.45	2	cephalosporin; semisynthetic derivative	antibacterial drug
fropenem [no description available]	2.05	1	faropenem
ljc 10627 biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.	2.05	1	carbapenems; organic sulfide; pyrazolotriazole	antibacterial drug
sanfetrinem sanfetrinem: orally absorbed hexetil ester of GV-104326	2.05	1
panipenem panipenem: synthetic cpd; structure given in first source	2.45	2	organic molecular entity
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	3.14	5	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	2.05	1	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
garenoxacin garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.	2.05	1	aromatic ether; cyclopropanes; isoindoles; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; non-steroidal anti-inflammatory drug
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	3.14	5	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	2.08	1	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	3.14	5	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	2.45	2
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.74	3	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
hmr 3647 [no description available]	2.03	1
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	2.03	1	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	2.05	1	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
cefixime [no description available]	2.04	1	cephalosporin	antibacterial drug; drug allergen
cefuroxime [no description available]	3.3	6	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	2.05	1	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.04	1	cephalosporin; oxime O-ether	antibacterial drug
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	3.3	6	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
cefpodoxime [no description available]	2.73	3	carboxylic acid; cephalosporin	antibacterial drug
s 1006 S 1006: structure given in first source. cefcapene : A cephalosporin compound having (carbamoyloxy)methyl and N-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino side-groups. It is used (generally as the corresponnding pivaloyloxymethyl ester prodrug) as an oral antibacterial.	2.45	2	1,3-thiazoles; carbamate ester; carboxylic acid; cephalosporin; enamide; secondary carboxamide	antibacterial drug
nitrocefin nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source	2.05	1
cefdinir [no description available]	3.14	5	cephalosporin; ketoxime	antibacterial drug
cefozopran [no description available]	2.04	1	cephalosporin; imidazopyridazine; thiadiazoles
tebipenem tebipenem: an oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae; structure in first source	2.97	4
rwj 54428 RWJ 54428: structure in first source	2.05	1
l 084 L 084: an oral carbapenem with a 1-(1,3-thiazolin-2-yl)azetidin-3-ylthio group at the C-2 position; structure in first source	2.08	1	carbapenems; pivaloyloxymethyl ester
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.04	1
ceftobiprole ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).	2.05	1	cephalosporin; thiadiazoles	antimicrobial agent

Condition	Indicated	Relationship Strength	Studies
Infections, Respiratory [description not available]	0	2.45	2
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	0	2.45	2
E coli Infections [description not available]	0	2.04	1
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	0	2.04	1
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	1	4.04	1
Acute Liver Injury, Drug-Induced [description not available]	0	2.06	1
Adverse Drug Event [description not available]	0	2.06	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.06	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	2.06	1
Benign Neoplasms [description not available]	0	3.03	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	3.03	1

cefditoren pivoxil

Cross-References

Synonyms (67)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (1)

Potency Measurements

Ceullar Components (1)

Bioassays (224)

Research

Studies (18)

Market Indicators

Research Demand Index: 71.95

Study Types

Clinical Trials (3)

Trial Overview

cefditoren pivoxil

Cross-References

Synonyms (67)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (1)

Potency Measurements

Ceullar Components (1)

Bioassays (224)

Research

Studies (18)

Market Indicators

Research Demand Index: 71.95

Study Types

Clinical Trials (3)

Trial Overview

Related Drugs (41)

Related Conditions (11)